CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
| | | |

CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…